WARREN, N.J., June 12, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will participate on a panel, titled Emerging Landscape of Treatment Options in PAH, at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018, in New York City. The conference is taking place June 20-21, 2018, at The St. Regis New York.

Bellerophon Presentation DetailsTitle: Emerging Landscape of Treatment Options in PAHDate: Wednesday, June 20, 2018Time: 9:00am-10:00am Eastern TimeLocation: The St. Regis New York, Library Room

About BellerophonBellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of PAH, for which the Company has commenced Phase 3 clinical trials. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD), both of which are in Phase 2 development. For more information, please visit www.bellerophon.com.

ContactBellerophon TherapeuticsFabian Tenenbaum, Chief Executive Officer(908) 574-4767

LifeSci AdvisorsBrian Ritchie212-915-2578 britchie@lifesciadvisors.com